Skip to main content
Top
Published in: Pediatric Nephrology 3/2005

01-03-2005 | Review

The growth hormone-insulin like growth factor axis revisited: lessons from IGF-1 and IGF-1 receptor gene targeting

Authors: Shoshana Yakar, Hyunsook Kim, Hong Zhao, Yuka Toyoshima, Patricia Pennisi, Oksana Gavrilova, Derek LeRoith

Published in: Pediatric Nephrology | Issue 3/2005

Login to get access

Abstract

We have created a liver-specific igf1 gene-deletion mouse model (LID) with markedly reduced circulating IGF-I levels. They demonstrate that while they have normal growth and development they develop insulin resistance secondary to the elevation of circulating growth hormone. When mated with an acid-labile subunit (ALS) gene-deleted mouse they also show osteopenia suggesting that circulating IGF-I levels play a significant role in bone formation. In a separate transgenic mouse we created a model of severe insulin resistance and type 2 diabetes by the overexpression of a dominant-negative IGF-I receptor in skeletal muscle. In this model we show that lipotoxicity plays a major role in the progression of the disease and is affected by treatment with a fibrate, which reverses the insulin resistance and diabetic state. These models are therefore very useful in studying human physiology and disease states.
Literature
1.
go back to reference Daughaday WH, Hall K, Raben MS, Salmon WD Jr, Brande JL van den, Wyk JJ van (1972) Somatomedin: proposed designation for sulphation factor. Nature 235:107PubMed Daughaday WH, Hall K, Raben MS, Salmon WD Jr, Brande JL van den, Wyk JJ van (1972) Somatomedin: proposed designation for sulphation factor. Nature 235:107PubMed
2.
go back to reference Le Roith D, Bondy C, Yakar S, Liu JL, Butler A (2001) The somatomedin hypothesis: 2001. Endocr Rev 22:53–74CrossRefPubMed Le Roith D, Bondy C, Yakar S, Liu JL, Butler A (2001) The somatomedin hypothesis: 2001. Endocr Rev 22:53–74CrossRefPubMed
3.
go back to reference Yakar S, Liu JL, Stannard B, Butler A, Accili D, Sauer B, Le Roith D (1999) Normal growth and development in the absence of hepatic insulin-like growth factor I. Proc Natl Acad Sci USA 96:7324–7329 Yakar S, Liu JL, Stannard B, Butler A, Accili D, Sauer B, Le Roith D (1999) Normal growth and development in the absence of hepatic insulin-like growth factor I. Proc Natl Acad Sci USA 96:7324–7329
4.
go back to reference Yakar S, Rosen CJ, Beamer WG, Ackert-Bicknell CL, Wu Y, Liu JL, Ooi GT, Setser J, Frysty J, Boisclair YR, Le Roith D (2002) Circulating levels of IGF-1 directly regulate bone growth and density. J Clin Invest 110:771–781CrossRefPubMed Yakar S, Rosen CJ, Beamer WG, Ackert-Bicknell CL, Wu Y, Liu JL, Ooi GT, Setser J, Frysty J, Boisclair YR, Le Roith D (2002) Circulating levels of IGF-1 directly regulate bone growth and density. J Clin Invest 110:771–781CrossRefPubMed
5.
go back to reference Yakar S, Liu JL, Fernandez AM, Wu Y, Schally AV, Frystyk J, Chernausek SD, Meija W, Le Roith D (2001) Liver-specific igf-1 gene deletion leads to muscle insulin insensitivity. Diabetes 50:1110–1118PubMed Yakar S, Liu JL, Fernandez AM, Wu Y, Schally AV, Frystyk J, Chernausek SD, Meija W, Le Roith D (2001) Liver-specific igf-1 gene deletion leads to muscle insulin insensitivity. Diabetes 50:1110–1118PubMed
6.
go back to reference Yakar S, Setser J, Zhao H, Stannard B, Haluzik M, Glatt V, Bouxsein ML, Kopchick JJ, Le Roith D (2004) Inhibition of growth hormone action improves insulin sensitivity in liver IGF-1-deficient mice. J Clin Invest 113:96–105CrossRefPubMed Yakar S, Setser J, Zhao H, Stannard B, Haluzik M, Glatt V, Bouxsein ML, Kopchick JJ, Le Roith D (2004) Inhibition of growth hormone action improves insulin sensitivity in liver IGF-1-deficient mice. J Clin Invest 113:96–105CrossRefPubMed
7.
go back to reference Haluzik M, Yakar S, Gavrilova O, Setser J, Boisclair Y, LeRoith D (2003) Insulin resistance in the liver-specific IGF-1 gene-deleted mouse is abrogated by deletion of the acid-labile subunit of the IGF-binding protein-3 complex: relative roles of growth hormone and IGF-1 in insulin resistance. Diabetes 52:2483–2489PubMed Haluzik M, Yakar S, Gavrilova O, Setser J, Boisclair Y, LeRoith D (2003) Insulin resistance in the liver-specific IGF-1 gene-deleted mouse is abrogated by deletion of the acid-labile subunit of the IGF-binding protein-3 complex: relative roles of growth hormone and IGF-1 in insulin resistance. Diabetes 52:2483–2489PubMed
8.
go back to reference Kato H, Faria TN, Stannard B, Roberts CT Jr, LeRoith D (1993) Role of tyrosine kinase activity in signal transduction by the insulin-like growth factor-I (IGF-1) receptor. Characterization of kinase-deficient IGF-1 receptors and the action of an IGF-1-mimetic antibody (alpha IR-3). J Biol Chem 268:2655–2661PubMed Kato H, Faria TN, Stannard B, Roberts CT Jr, LeRoith D (1993) Role of tyrosine kinase activity in signal transduction by the insulin-like growth factor-I (IGF-1) receptor. Characterization of kinase-deficient IGF-1 receptors and the action of an IGF-1-mimetic antibody (alpha IR-3). J Biol Chem 268:2655–2661PubMed
9.
go back to reference Fernandez AM, Kim JK, Yakar S, Dupont J, Hernandez-Sanchez C, Castle AL, Filmore J, Shulman GI, Le Roith D (2001) Functional inactivation of the IGF-1 and insulin receptors in skeletal muscle causes type 2 diabetes. Genes Dev 15:1926–1934CrossRefPubMed Fernandez AM, Kim JK, Yakar S, Dupont J, Hernandez-Sanchez C, Castle AL, Filmore J, Shulman GI, Le Roith D (2001) Functional inactivation of the IGF-1 and insulin receptors in skeletal muscle causes type 2 diabetes. Genes Dev 15:1926–1934CrossRefPubMed
10.
go back to reference Kim H, Haluzik M, Asghar Z, Yau D, Joseph JW, Fernandez AM, Reitman ML, Yakar S, Stannard B, Heron-Milhavet L, Wheeler MB, Le Roith D (2003) Peroxisome proliferator-activated receptor-alpha agonist treatment in a transgenic model of type 2 diabetes reverses the lipotoxic state and improves glucose homeostasis. Diabetes 52:1770–1778PubMed Kim H, Haluzik M, Asghar Z, Yau D, Joseph JW, Fernandez AM, Reitman ML, Yakar S, Stannard B, Heron-Milhavet L, Wheeler MB, Le Roith D (2003) Peroxisome proliferator-activated receptor-alpha agonist treatment in a transgenic model of type 2 diabetes reverses the lipotoxic state and improves glucose homeostasis. Diabetes 52:1770–1778PubMed
Metadata
Title
The growth hormone-insulin like growth factor axis revisited: lessons from IGF-1 and IGF-1 receptor gene targeting
Authors
Shoshana Yakar
Hyunsook Kim
Hong Zhao
Yuka Toyoshima
Patricia Pennisi
Oksana Gavrilova
Derek LeRoith
Publication date
01-03-2005
Publisher
Springer-Verlag
Published in
Pediatric Nephrology / Issue 3/2005
Print ISSN: 0931-041X
Electronic ISSN: 1432-198X
DOI
https://doi.org/10.1007/s00467-004-1613-y

Other articles of this Issue 3/2005

Pediatric Nephrology 3/2005 Go to the issue